Quantcast
Connect with us

Drug makers are jacking up prices months after Trump boasted they were rolling them back at his request

Published

on

Big Pharma companies are announcing that they are jacking up drug prices just months after President Donald Trump took to Twitter and boasted that they would roll them back or hold them down at his request.

Just as car manufacturers are shuttering plants after Trump claimed that he was responsible for a surge in manufacturing jobs, drug manufacturers such as Pfizer and Merck announced this week that they will increase pricing — contrary to Trump’s promise of price decreases.

ADVERTISEMENT

According to business columnist Micheal Hiltzik of the Los Angeles Times, the manufacturers pulled a fast one when they told Trump they would defer planned price increases back in May, only to drop the bomb before the end of the year.

On July 10th, Trump tweeted: “Just talked with Pfizer CEO and @SecAzar on our drug pricing blueprint. Pfizer is rolling back price hikes, so American patients don’t pay more. We applaud Pfizer for this decision and hope other companies do the same. Great news for the American people!”

But industry observers point out that Trump lied when he bragged about prices “rolling back.”

ADVERTISEMENT

As Hiltzik writes, “Instead, the company said it would ‘defer’ price increases on 41 drug formulations it had scheduled for July 1 until either Trump’s ‘blueprint to lower drug prices’ went into effect or the end of the year, whichever came sooner.”

He points out that Peter Maybarduk of advocacy group Public Citizen noted at the time, “Pfizer is only deferring price increases — not canceling them, and certainly not lowering its prices.”

According to University of Pittsburgh pharmaceutical policy expert Walid Gellad, drug companies humored the president while making plans to go ahead with raising prices after getting kudos from Trump.

ADVERTISEMENT

“Making promises to the president is not how you fix a fundamental market problem,” Gellad explained.

The Times report notes that Merck manipulated public opinion — and possibly the president — by playing fast and loose with the truth.

ADVERTISEMENT

“Merck, in its July 20 announcement of price cuts, built itself a rather more elaborate loophole. The company said it would not increase the average net price of its entire portfolio of drugs by more than inflation annually,” Hikltzik wrote. “It dressed up the announcement by lowering the price of Zepatier, a hepatitis C treatment, by 60% and of six other drugs by 10%.”

He then noted that the seven drugs listed were small, unpopular and unprofitable formulations that account for very little of their sales, writing, “Zepatier sales had fallen so low by the first quarter of this year that Merck listed the drug’s U.S. sales in its quarterly financial report as essentially zero.”

Addressing just Merck’s announced increase, and using its 2017 revenues as a guide, Hiltzik said the announced increases “will fatten Merck’s profits by about $357 million, or 15%.”

ADVERTISEMENT

You can read more here.


Report typos and corrections to: [email protected].
READ COMMENTS - JOIN THE DISCUSSION
Continue Reading

Breaking Banner

Lindsey Graham promises Fox viewers a new investigation into Andrew McCabe despite the Justice Dept clearing him

Published

on

Appearing on the Fox Business channel with host Maria Bartiromo, Sen. Lindsey Graham (R-SC) promised viewers he fully intends to use his position as the head of the Senate Judiciary Committee to launch his own investigation into former Deputy Director of the Federal Bureau of Investigation Andrew McCabe despite the former law enforcement official already having been cleared by the Justice Department.

Complaining that the controversial Steele dossier was based on " a bunch of bar-talk and hearsay," Graham said he plans to call -- at the very least -- McCabe and former FBI Director James Comey in to be grilled by his committee.

Continue Reading

2020 Election

‘Kiss Florida goodbye’: Voto Latino head warns Democrats of coming 2020 debacle

Published

on

Appearing on MSNBC's "AM Joy," Voto Latino CEO María Teresa Kumar said Democrats should not count on taking Florida's 29 electoral votes in the upcoming 2020 presidential election if Sen. Bernie Sanders (I-VT) is the at the top of the ticket.

During a fairly contentious panel discussion on the viability of Sanders as a candidate due to self-identifying as a democratic socialist, Kumar claimed that would not play well Florida's Latino community.

"All I can think about when David [Corn] was unpacking it for us, we can all agree is you can kiss Florida goodbye," she explained. "I say that, Floridians -- Latinos that have fled socialism, they have fled and they are in Florida and they have sensibilities that are different from the rest of the Latino community."

Continue Reading
 

Breaking Banner

CNN’s Bakari Sellers schools Rick Santorum over claim Trump is not part of the ‘extreme hard right’

Published

on

During a panel discussion on CNN's State of the Union, contributor Bakari Sellers set fellow panelist Rick Santorum straight after he tried to claim that Donald Trump doesn't take far-right positions.

Following a discussion on Sen. Bernie Sanders' Nevada caucus win, Santorum tried to note the major differences between Trump and Sen. Bernie Sanders.

Responding to conservative commentator Linda Chavez who called both Sanders and Trump "two angry people," Santorum remarked, "I wanted to take issue with what Linda said: two angry folks representing the extremes, and I would agree with that, with Bernie Sanders, and he is representing, no question, the extreme of the Democratic Party and he says that he is a socialist and he is angry, I agree."

Continue Reading
 
 
close-image